Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.64 |
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.64 |
| ▸ | METAP2 | P50579 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.52 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984253 | 0.99 | KDM1A (0.69) | KDM1AMCL1BCL2A1METAP2MEN1 | |
| SCHEMBL4650217 | 0.83 | KDM1A (0.71) | KDM1AMCL1BCL2A1METAP2MEN1 | |
| SCHEMBL18151773 | 0.79 | MCL1 (1.00) | KDM1AMCL1BCL2A1MEN1ALDH1A1 | |
| SCHEMBL9326592 | 0.79 | KDM1A (0.56) | KDM1AMCL1BCL2A1MEN1ALDH1A1 | |
| SCHEMBL16495860 | 0.78 | METAP2 (0.73) | KDM1AMCL1BCL2A1METAP2ACLY | |
| SCHEMBL4565923 | 0.76 | METAP2 (0.69) | MCL1BCL2A1METAP2MEN1POLB | |
| SCHEMBL2009251 | 0.75 | METAP2 (1.00) | MCL1BCL2A1METAP2ALDH1A1 | |
| SCHEMBL1139356 | 0.75 | ACLY (0.78) | METAP2ACLY | |
| SCHEMBL1466906 | 0.74 | ALDH1A1 (0.72) | MCL1METAP2MEN1ALDH1A1POLB | |
| SCHEMBL4098914 | 0.73 | ACMSD (0.53) | KDM1AMCL1BCL2A1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | claimed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | KDM1A 3419/4885MCL1 1545/4885BCL2A1 1450/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | KDM1A 3419/4885MCL1 1545/4885BCL2A1 1450/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | KDM1A 3419/4885MCL1 1545/4885BCL2A1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.